copied pr from monroe1 re tuesday dr been intervi
Post# of 154062
(Total Views: 760)
Posted On: 09/20/2020 9:56:07 PM
copied pr from monroe1 re tuesday dr been interview looks like a barnburner folks-a biggie
CYDY Dr Pourhassan CMO Dr Kelly to Appear on DrBeen Webcast Tuesday, September 22, 2020
Download as PDF
September 20, 2020 9:14pm EDT
VANCOUVER, Washington, Sept. 20, 2020 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” or the “Company"
, a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, announced today Nader Pourhassan, Ph.D., President and Chief Executive Officer and Scott A. Kelly, M.D., Chairman, Chief Medical Officer and Head of Business Development, of CytoDyn will be interviewed on the DrBeen webcast hosted by Mobeen Syed, M.D., M.S. on Tuesday, September 22, 2020 at 6:00 pm PT.
Topics to be covered:
1) CD10: Mild-to-moderate COVID-19 results (U.K., U.S., Philippines, Canada)
2) CD12: Upcoming interim analysis
3) COVID-19: Upcoming trial in “long-haulers”
4) COVID-19: Phase 3 trial in Moderate
5) HIV BLA submission to U.K. and U.S.
6) Leronlimab for stroke victims (blood brain barrier)
7) Upcoming NASH trial and timelines
Future of cancer trials with leronlimab
The interview will be available simultaneously on two channels:
YouTube: DrBeen Medical Lectures
Link: https://www.youtube.com/c/USMLEOnline
Facebook: DrBeen Medical
Link: https://m.facebook.com/drbeenmedical
Date: Tuesday, September 22, 2020
Time: 6:00 pm PT
About Coronavirus Disease 2019
CytoDyn completed its Phase 2 clinical trial (CD10) for COVID-19, a double-blinded, randomized clinical trial for mild-to-moderate patients in the U.S. which produced statistically significant results for NEWS2. Enrollment continues in its Phase 3 randomized clinical trial for the severe-to-critically ill COVID-19 population in several hospitals throughout the U.S.; an interim analysis on the first 195 patients will be announced by mid-October.
About Leronlimab (PRO 140)
The FDA has granted a Fast Track designation to CytoDyn for two potential indications of leronlimab for critical illnesses. The first indication is a combination therapy with HAART for HIV-infected patients and the second is for metastatic triple-negative breast cancer. Leronlimab is an investigational humanized IgG4 mAb that blocks CCR5, a cellular receptor that is important in HIV infection, tumor metastases, and other diseases, including NASH. Leronlimab has completed nine clinical trials in over 800 people and met its primary endpoints in a pivotal Phase 3 trial (leronlimab in combination with standard antiretroviral therapies in HIV-infected treatment-experienced patients).
In the setting of HIV/AIDS, leronlimab is a viral-entry inhibitor; it masks CCR5, thus protecting healthy T cells from viral infection by blocking the predominant HIV (R5) subtype from entering those cells. Leronlimab has been the subject of nine clinical trials, each of which demonstrated that leronlimab could significantly reduce or control HIV viral load in humans. The leronlimab antibody appears to be a powerful antiviral agent leading to potentially fewer side effects and less frequent dosing requirements compared with daily drug therapies currently in use.
In the setting of cancer, research has shown that CCR5 may play a role in tumor invasion, metastases, and tumor microenvironment control. Increased CCR5 expression is an indicator of disease status in several cancers. Published studies have shown that blocking CCR5 can reduce tumor metastases in laboratory and animal models of aggressive breast and prostate cancer. Leronlimab reduced human breast cancer metastasis by more than 98% in a murine xenograft model. CytoDyn is, therefore, conducting a Phase 1b/2 human clinical trial in metastatic triple-negative breast cancer and was granted Fast Track designation in May 2019.
CYDY Dr Pourhassan CMO Dr Kelly to Appear on DrBeen Webcast Tuesday, September 22, 2020
Download as PDF
September 20, 2020 9:14pm EDT
VANCOUVER, Washington, Sept. 20, 2020 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” or the “Company"
, a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, announced today Nader Pourhassan, Ph.D., President and Chief Executive Officer and Scott A. Kelly, M.D., Chairman, Chief Medical Officer and Head of Business Development, of CytoDyn will be interviewed on the DrBeen webcast hosted by Mobeen Syed, M.D., M.S. on Tuesday, September 22, 2020 at 6:00 pm PT. Topics to be covered:
1) CD10: Mild-to-moderate COVID-19 results (U.K., U.S., Philippines, Canada)
2) CD12: Upcoming interim analysis
3) COVID-19: Upcoming trial in “long-haulers”
4) COVID-19: Phase 3 trial in Moderate
5) HIV BLA submission to U.K. and U.S.
6) Leronlimab for stroke victims (blood brain barrier)
7) Upcoming NASH trial and timelines
Future of cancer trials with leronlimab The interview will be available simultaneously on two channels:
YouTube: DrBeen Medical Lectures
Link: https://www.youtube.com/c/USMLEOnline
Facebook: DrBeen Medical
Link: https://m.facebook.com/drbeenmedical
Date: Tuesday, September 22, 2020
Time: 6:00 pm PT
About Coronavirus Disease 2019
CytoDyn completed its Phase 2 clinical trial (CD10) for COVID-19, a double-blinded, randomized clinical trial for mild-to-moderate patients in the U.S. which produced statistically significant results for NEWS2. Enrollment continues in its Phase 3 randomized clinical trial for the severe-to-critically ill COVID-19 population in several hospitals throughout the U.S.; an interim analysis on the first 195 patients will be announced by mid-October.
About Leronlimab (PRO 140)
The FDA has granted a Fast Track designation to CytoDyn for two potential indications of leronlimab for critical illnesses. The first indication is a combination therapy with HAART for HIV-infected patients and the second is for metastatic triple-negative breast cancer. Leronlimab is an investigational humanized IgG4 mAb that blocks CCR5, a cellular receptor that is important in HIV infection, tumor metastases, and other diseases, including NASH. Leronlimab has completed nine clinical trials in over 800 people and met its primary endpoints in a pivotal Phase 3 trial (leronlimab in combination with standard antiretroviral therapies in HIV-infected treatment-experienced patients).
In the setting of HIV/AIDS, leronlimab is a viral-entry inhibitor; it masks CCR5, thus protecting healthy T cells from viral infection by blocking the predominant HIV (R5) subtype from entering those cells. Leronlimab has been the subject of nine clinical trials, each of which demonstrated that leronlimab could significantly reduce or control HIV viral load in humans. The leronlimab antibody appears to be a powerful antiviral agent leading to potentially fewer side effects and less frequent dosing requirements compared with daily drug therapies currently in use.
In the setting of cancer, research has shown that CCR5 may play a role in tumor invasion, metastases, and tumor microenvironment control. Increased CCR5 expression is an indicator of disease status in several cancers. Published studies have shown that blocking CCR5 can reduce tumor metastases in laboratory and animal models of aggressive breast and prostate cancer. Leronlimab reduced human breast cancer metastasis by more than 98% in a murine xenograft model. CytoDyn is, therefore, conducting a Phase 1b/2 human clinical trial in metastatic triple-negative breast cancer and was granted Fast Track designation in May 2019.
(4)
(0)